• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

弥漫性皮肤系统性硬化症中皮肤评分变化与疾病转归的关系:潜在线性轨迹模型的应用

Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model.

作者信息

Shand Lynne, Lunt Mark, Nihtyanova Svetlana, Hoseini Mansour, Silman Alan, Black Carol M, Denton Christopher P

机构信息

Royal Free Hospital, London, UK.

出版信息

Arthritis Rheum. 2007 Jul;56(7):2422-31. doi: 10.1002/art.22721.

DOI:10.1002/art.22721
PMID:17599771
Abstract

OBJECTIVE

To explore the relationship between changes in the severity of skin disease and morbidity and mortality in patients with diffuse cutaneous systemic sclerosis (dcSSc).

METHODS

From a large single-center cohort, we identified 225 patients with dcSSc for whom serial clinical information was available from within 24 months of the onset of the first non-Raynaud's phenomenon manifestation of SSc. The end points analyzed included death and heart, lung, kidney, and gastrointestinal tract involvement. Latent linear trajectory modeling (LTM) was applied to identify patients with a similar trajectory of modified Rodnan skin thickness score (MRSS) changes over the first 3 years of followup. Clinical outcomes were compared between 3 different LTM subgroups.

RESULTS

LTM permitted classification of 131 patients (58%) into 1 of 3 subgroups with different skin score trajectories. Survival was lowest in the subgroup of patients who had a high baseline skin score and experienced little improvement during followup (P = 0.003). However, the frequency of clinical end points was similar in the subgroup with the most favorable trajectory (i.e., a low initial MRSS and subsequent improvement) and the subgroup with a high baseline MRSS and no improvement. Interestingly, the end point frequency was greatest in the subgroup with a high initial MRSS and subsequent improvement, suggesting that sustained severe skin disease does not necessarily predict the number of visceral complications, and that the relationship between the skin score and internal organ involvement in dcSSc is more complex than previously thought.

CONCLUSION

Although mortality was highest among patients with the worst skin-related outcomes, no simple relationship between burden of disease and change in skin score was observed.

摘要

目的

探讨弥漫性皮肤系统性硬化症(dcSSc)患者皮肤疾病严重程度变化与发病率及死亡率之间的关系。

方法

从一个大型单中心队列中,我们确定了225例dcSSc患者,这些患者在系统性硬化症首次非雷诺现象表现出现后的24个月内有系列临床信息。分析的终点包括死亡以及心脏、肺、肾脏和胃肠道受累情况。应用潜在线性轨迹模型(LTM)来识别在随访的前3年中改良罗德南皮肤厚度评分(MRSS)变化轨迹相似的患者。比较了3个不同LTM亚组之间的临床结局。

结果

LTM可将131例患者(58%)分为3个具有不同皮肤评分轨迹的亚组之一。基线皮肤评分高且随访期间改善甚微的亚组患者生存率最低(P = 0.003)。然而,轨迹最有利的亚组(即初始MRSS低且随后有所改善)和基线MRSS高且无改善的亚组临床终点频率相似。有趣的是,初始MRSS高且随后有所改善的亚组终点频率最高,这表明持续的严重皮肤疾病不一定能预测内脏并发症的数量,并且dcSSc中皮肤评分与内脏器官受累之间的关系比之前认为的更为复杂。

结论

尽管皮肤相关结局最差的患者死亡率最高,但未观察到疾病负担与皮肤评分变化之间存在简单的关系。

相似文献

1
Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model.弥漫性皮肤系统性硬化症中皮肤评分变化与疾病转归的关系:潜在线性轨迹模型的应用
Arthritis Rheum. 2007 Jul;56(7):2422-31. doi: 10.1002/art.22721.
2
Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.抗拓扑异构酶I抗体阳性的系统性硬化症患者的临床亚组、皮肤厚度进展率及血清抗体水平
Arthritis Rheum. 2007 Aug;56(8):2740-6. doi: 10.1002/art.22747.
3
Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register.皮肤硬化对于识别具有严重临床表现的系统性硬化症(SSc)患者价值有限——德国系统性硬化症网络(DNSS)登记处一个特定患者亚组的分析。
Rheumatology (Oxford). 2009 Jan;48(1):70-3. doi: 10.1093/rheumatology/ken408.
4
Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial.皮肤厚度评分作为系统性硬化症预后的预测指标及相关因素:高剂量与低剂量青霉胺试验
Arthritis Rheum. 2000 Nov;43(11):2445-54. doi: 10.1002/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q.
5
The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial.健康评估问卷残疾指数是系统性硬化症试验中高剂量与低剂量青霉胺治疗结果的一个预测指标且与之相关。
Arthritis Rheum. 2001 Mar;44(3):653-61. doi: 10.1002/1529-0131(200103)44:3<653::AID-ANR114>3.0.CO;2-Q.
6
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.硬皮病肾危象的预测因素及预后:早期弥漫性系统性硬化症试验中高剂量与低剂量青霉胺的对比研究
Arthritis Rheum. 2002 Nov;46(11):2983-9. doi: 10.1002/art.10589.
7
Severe organ involvement in systemic sclerosis with diffuse scleroderma.系统性硬化症伴弥漫性硬皮病的严重器官受累。
Arthritis Rheum. 2000 Nov;43(11):2437-44. doi: 10.1002/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U.
8
Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.重组人抗转化生长因子β1抗体疗法治疗系统性硬化症:CAT-192的多中心、随机、安慰剂对照I/II期试验
Arthritis Rheum. 2007 Jan;56(1):323-33. doi: 10.1002/art.22289.
9
Determinants of morbidity and mortality of systemic sclerosis in Canada.加拿大系统性硬化症发病率和死亡率的决定因素。
Semin Arthritis Rheum. 2010 Feb;39(4):269-77. doi: 10.1016/j.semarthrit.2008.06.002. Epub 2008 Aug 15.
10
A longitudinal follow-up of hand involvement and activities of daily living in early systemic sclerosis.早期系统性硬化症中手受累和日常生活活动的纵向随访。
Scand J Rheumatol. 2009;38(4):304-10. doi: 10.1080/03009740802695466.

引用本文的文献

1
Characterization of a pathogenic nonmigratory fibroblast population in systemic sclerosis skin.系统性硬化症皮肤中致病性非迁移性成纤维细胞群体的特征分析
JCI Insight. 2025 Apr 15;10(10). doi: 10.1172/jci.insight.185618. eCollection 2025 May 22.
2
Correlation Between the Peak of Skin Thickness Progression Rate and Onset of Cardiopulmonary Involvement in Thai Systemic Sclerosis Patients.泰国系统性硬化症患者皮肤厚度进展率峰值与心肺受累发病之间的相关性
J Clin Med. 2025 Mar 27;14(7):2281. doi: 10.3390/jcm14072281.
3
and Gene Polymorphisms in Systemic Sclerosis.
以及系统性硬化症中的基因多态性
Balkan J Med Genet. 2025 Mar 6;27(2):59-68. doi: 10.2478/bjmg-2024-0017. eCollection 2024 Dec.
4
Multimodal Screening for Pulmonary Arterial Hypertension in Systemic Scleroderma: Current Methods and Future Directions.系统性硬化症中肺动脉高压的多模式筛查:当前方法与未来方向
Medicina (Kaunas). 2024 Dec 27;61(1):19. doi: 10.3390/medicina61010019.
5
The diagnostic value and clinical relevance of high frequency ultrasound and shear wave elastography in systemic sclerosis: an observational monocentric study.高频超声和剪切波弹性成像在系统性硬化症中的诊断价值及临床相关性:一项观察性单中心研究。
Clin Rheumatol. 2024 Dec;43(12):3759-3769. doi: 10.1007/s10067-024-07145-6. Epub 2024 Oct 5.
6
Cross-tissue organization of myeloid cells in scleroderma and related fibrotic diseases.硬皮病及相关纤维化疾病中髓系细胞的跨组织分布。
Curr Opin Rheumatol. 2024 Nov 1;36(6):379-386. doi: 10.1097/BOR.0000000000001047. Epub 2024 Sep 11.
7
An Assessment of Administration Route on MSC-sEV Therapeutic Efficacy.MSC-sEV 治疗功效的给药途径评估。
Biomolecules. 2024 May 24;14(6):622. doi: 10.3390/biom14060622.
8
Severity and impact of digestive impairment perceived by patients with systemic sclerosis: a cross-sectional study.系统性硬化症患者感知的消化功能障碍的严重程度和影响:一项横断面研究。
BMJ Open. 2024 Apr 29;14(4):e083419. doi: 10.1136/bmjopen-2023-083419.
9
Testing a candidate composite serum protein marker of skin severity in systemic sclerosis.检测系统性硬化症皮肤严重程度的复合血清蛋白候选标志物。
Rheumatol Adv Pract. 2024 Mar 9;8(2):rkae039. doi: 10.1093/rap/rkae039. eCollection 2024.
10
Systemic sclerosis is a risk factor of incident psoriasis: results from a nationwide cohort study.系统性硬化症是银屑病发病的一个危险因素:一项全国性队列研究的结果。
Front Immunol. 2023 Dec 14;14:1326298. doi: 10.3389/fimmu.2023.1326298. eCollection 2023.